We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a ...

As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a ...

Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 3,940,000 ...

JPMorgan Chase & Co. raised its holdings in shares of Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) by 26.8% during the 3rd quarter, according to the company in its most recent 13F filing with ...

Bicycle Therapeutics' BT8009 offers strong safety and efficacy. Find out why BCYC stock could be a buy, despite recent volatility and awaiting mid-2025 data.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on February 3, 2025, the Compensation Committee of the company’s Board of Directors ...

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on February 3, 2025, the Compensation Committee of the company’s Board of Directors granted to 18 new employees inducement awards ...

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on February 3, 2025, the Compensation Committee of the company’s Board of Directors granted to 18 new employees inducement awards ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary ...